AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Recruitingn/aAges any - anyAllAstraZeneca
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medica

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Advanced (unresectable or metastatic) non-small cell lung carcinoma * First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026) * \> 18 years old * Data available in electronic medical records. Exclusion Criteria: * Localized disease amenable to local treatment * Non-epithelial histology * Small cell carcinoma * Neuroendocrine tumor * Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

7 sites
Research Site
Recife, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Salvador, Brazil
Research Site
Sรฃo Paulo, Brazil
Research Site
Sรฃo Paulo, Brazil
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy